Exchange Traded Concepts LLC Sells 909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Exchange Traded Concepts LLC trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,806 shares of the biopharmaceutical company’s stock after selling 909 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Alnylam Pharmaceuticals were worth $915,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALNY. Fulton Bank N.A. lifted its holdings in Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 46 shares during the last quarter. Wedmont Private Capital increased its holdings in Alnylam Pharmaceuticals by 10.6% in the 2nd quarter. Wedmont Private Capital now owns 1,761 shares of the biopharmaceutical company’s stock worth $565,000 after purchasing an additional 169 shares in the last quarter. Swedbank AB boosted its position in shares of Alnylam Pharmaceuticals by 7.2% during the 2nd quarter. Swedbank AB now owns 64,315 shares of the biopharmaceutical company’s stock valued at $20,972,000 after purchasing an additional 4,322 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Alnylam Pharmaceuticals by 14.3% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,808 shares of the biopharmaceutical company’s stock valued at $4,829,000 after purchasing an additional 1,851 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Alnylam Pharmaceuticals by 36.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 196 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 52 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 1.0%

ALNY stock opened at $454.41 on Wednesday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The business’s 50 day moving average price is $420.78 and its two-hundred day moving average price is $327.63. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $484.21. The company has a market capitalization of $59.56 billion, a price-to-earnings ratio of -183.97 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on ALNY shares. Piper Sandler increased their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Royal Bank Of Canada raised their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. The Goldman Sachs Group lifted their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. Finally, Jefferies Financial Group lifted their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research note on Monday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $439.58.

Insiders Place Their Bets

In other news, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company’s stock, valued at $362,390. This represents a 95.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 in the last three months. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.